Selexis names Yemi Onakunle as vp of strategic and market development

Former Diosynth and Lonza executive joins Swiss life science company

Geneva, Switzerland-based Selexis has hired Yemi Onakunle as vice president of strategic and market development. He will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

Onakunle has more than 15 years' experience in drug manufacturing and cell line development. Prior to joining Selexis, he was director of commercial development at Diosynth RTP and associate director of business development at Lonza Custom Manufacturing.

More recently, Onakunle was head of sales and marketing at Bachem Americas, a contract manufacturing organisation focusing on peptides and complex organic molecules.

Onakunle is a member of the board of directors of VLP Biotech, a vaccine development company based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies.

You may also like

Research & Development

Faron links up with Selexis to progress development of cancer antibody

Under the agreement, Faron will have access to the Selexis SUREtechnology platform and SURE CHO-M cell line
Manufacturing

JHL Biotech and Selexis form biologic drug development alliance

Will provide seamless services from cell line development to cGMP manufacturing
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Subscribe now